Resistance among isolates of frequently encountered members of the family Enterobacteriaceae to antibacterial drugs;Resistenz bei häufig isolierten enterobacteriaceae gegenüber breitspektrum-antibiotika

Chemotherapie Journal

Volumn 15, Issue 6, 2006, Pages 179-190

  Kresken, Michael ^a,b   Hafner, Dieter ^a,c   Schmitz, Franz Josef ^a,d   Wichelhaus, Thomas A ^a,e  

^a Campus Fachhochschule Bonn Rhein Sieg ^*

^b BONN RHEIN SIEG UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Muehlenkreiskliniken   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Aminoglycosides; Antibacterial agents; Carbapenems; Cephalosporins; Development of resistance; Enterobacteriaceae species; Fluoroquinolones

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULBACTAM PLUS SULBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EUROPE; HEALTH SURVEY; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LONGITUDINAL STUDY; MEDICAL SOCIETY; NONHUMAN; PREVALENCE; PROTEUS MIRABILIS;

EID: 33846173382     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Archibald L, Phillips L, Monnet D, McGowan Jr. JE, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States. Increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
2. Baquero F. Trends in antibiotic resistance of respiratory pathogens. An analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996;38(Suppl A):J17-32.
3. Bronzwaer SL, Cars O, Buchholz U, Molstad S, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002;3:278-82.
4. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60.
5. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical centre. J Clin Microbiol 2000;38:1791-6.
6. Deutsches Institut für Normung, Normenausschuss Medizin (NAMed). Methoden zur Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika. Teil 8. Mikrodilution. DIN 58940-8, Oktober 2002.
7. Deutsches Institut für Normung, Normenausschuss Medizin (NAMed). Methoden zur Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika. Teil 4. Bewertungsstufen für die minimale Hemmkonzentration - MHK-Grenzwerte von antibakteriellen Wirkstoffen. Beiblatt 1 zu DIN 58940-4, Februar 2004.
8. EARSS (European Antimicrobial Resistance Surveillance System) Annual Report 2004. http.//www.rivm.nl/earss/
9. Fachinformation Invanz®.
10. Goettsch W, van Pelt W, Nagelkerke N, Hendrix MG, et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 2000;46:223-8.
11. Gold HS, Moellering Jr. RC. Antimicrobial drug resistance. N Engl J Med 1996;335:1445-53.
12. Hughes JM, Tenover FC. Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations. Clin Infect Dis 1997;24(Suppl 1):S131-5.
13. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center. Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005;24:111-8.
14. Kresken M, Hafner D. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975-1995. Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Infection 1999;27(Suppl 2):S2-8.
15. Kresken M, Hafner D. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Fluorchinolonen (Ciprofloxacin) in Mitteleuropa. Chemother J 2002;11(Suppl 20):18-24.
16. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA für die Studiengruppe. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2001. Antiinfectives Intelligence, Bonn, 2003.
17. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA für die Studiengruppe. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2004. Antiinfectives Intelligence, Rheinbach, 2006.
18. Livermore DM, James D, Reacher M, Graham C, et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002;8:473-8.
19. Livermore DM. Tigecycline. What is it, and where should it be used? J Antimicrob Chemother 2005;56:611-4.
20. MacDougall C, Powell JP, Johnson CK, Edmond MB, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435-40.
21. Mahamat A, Lavigne JP, Fabbro-Peray P, Kinowski JM, et al. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital. Application of the dynamic regression model. Clin Microbiol Infect 2005;11:301-6.
22. Monnet DL, Archibald LK, Phillips L, Tenover F, et al. Antimicrobial use and resistance in eight US hospitals, complexities of analysis and modeling. Intensive care antimicrobial resistance epidemiology project and national nosocomial infections surveillance system hospitals. Infect Control Hosp Epidemiol 1998;19:388-94.
23. Pena C, Albareda JM, Pallares R, Pujol M, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-4.
24. Wise R, Andrews JM for the Synercid Resistance Surveillance Group. Local surveillance of antimicrobial resistance. Lancet 1998;352:657-8.